Unclear cancer risks of Hormonal Contraception

Key points
- Literature data no reported significant association of age at menarche, parity, age at first birth, and exogenous hormone use with bladder cancer risk.
- For postmenopausal women, early age at menopause (</=45 years) compared with late age at menopause (>/=50 years) was reported associated with a statistically significant increased risk of bladder cancer (incidence rate ratio = 1.63 ).
- Greater incidence of thyroid cancer in women than men, particularly evident during the reproductive years, has led to the suggestion that female hormones may increase the risk for this disease.
- Therfore, the data do not support the hypothesis that use of exogenous estrogens increases the risk of female thyroid cancer (130).
Literature data no reported significant association of age at menarche, parity, age at first birth, and exogenous hormone use with bladder cancer risk. Findings suggest that menopausal status and age at menopause may play a role in modifying bladder cancer risk among women (128).
For postmenopausal women, early age at menopause (</=45 years) compared with late age at menopause (>/=50 years) was reported associated with a statistically significant increased risk of bladder cancer (incidence rate ratio = 1.63 ). The association between age at menopause and bladder cancer risk could be modified by cigarette smoking status (1,129).
Greater incidence of thyroid cancer in women than men, particularly evident during the reproductive years, has led to the suggestion that female hormones may increase the risk for this disease.
A study estimating the relative risk of papillary thyroid cancer among users of exogenous hormones among 410 women aged 45 to 64 years, observed no association of use of ormonal contraceptives (HCs) or HRT with risk of papillary thyroid cancer.
{embed="ref/stat-menu-obgyn1"}
Among women less than 45 years of age, risk of papillary thyroid cancer was reduced in women who had ever used HCs (OR = 0.6); beyond the relation with ever-use, there was no further association with specific aspects of exposure such as estrogenic potency, latency, recency, age at first or last use, or use at the reference date.
Therfore, the data do not support the hypothesis that use of exogenous estrogens increases the risk of female thyroid cancer (130). The role of exogenous hormone exposures in the development of meningioma is unclear.
Little evidence of associations between meningioma and exogenous hormone exposures in women was found but did suggest that some hormonal exposures may influence tumor biology in those women who develop meningioma (131).
--
Rosa Sabatini and Giuseppe Loverro
Dept. Obstetrics and Gynecology,
General Hospital Policlinico-University of Bari, Italy
--
REFERENCES
- La Vecchiam, C., Negri, E., Franceschi, S., Parazzini, F. (1993). Long-term impact of reproductive factors on cancer risk. Int J Cancer, Jan 21, 53(2), 215-9.
- Medard, M.L., Ostrowska, L. (2007).Combined oral contraception and the risk of reproductive organs cancer in women .Ginekol Pol, Aug,78(8), 637-41.
- Casey, P.M., Cerhan, J.R., Pruthi, S. (2008). Oral contraceptive use and risk of breast cancer. Mayo Clin Proc,Jan,83),86-90
- Deligeoroglou, E., Michailidis, E., Creatsas, G. (2003).Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci,Nov,997,199-208.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Women's Health →
NewsHormonal contraception ups clot risk in blacks
A study of African American women shows that use of birth control pills and other forms of hormonal contraception, and possibly the presence of the sickle cell trait, increase the risk of venous thromboembolism (VTE) -…
18 July 2009
OverviewHormonal Contraception
Every health.am guide, reference page and news story about hormonal contraception.
NewsNearly 10 percent of women live too far from access to gynecologic cancer care
More than one-third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly…
12 June 2015




